NCT03842202View on ClinicalTrials.gov

A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

February 15, 2019

Primary Completion Date

November 4, 2019

Study Completion Date

November 4, 2019

Conditions
OverweightObesity
Interventions
DRUG

Semaglutide

Participants will receive gradually increasing doses of semaglutide (subcutaneous \[s.c.\], in the thigh, abdomen or upper arm) injection once weekly, until they reach a dose of level of 2.4 mg, which they will continue for 5 weeks.

DRUG

Placebo

Participants will receive once weekly injections of semaglutide matched placebo.

Trial Locations (1)

14050

Novo Nordisk Investigational Site, Berlin

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY